Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Product Type
  5. Monoclonal Antibody

Monoclonal Antibody

Thumbnail
March 16, 2023

World ADC 2023 – targeting the folate receptor rises from the ashes

Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.

Thumbnail
March 16, 2023

Biologics look set to lose US drug price negotiation loophole

Article image
Vantage logo
March 10, 2023

Polivy adcom: no overall survival, no problem

A US adcom surprisingly backs Polivy’s front-line use, and blockbuster sales could follow.

Article image
Vantage logo
February 27, 2023

CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies

GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer.

Article image
Vantage logo
February 14, 2023

The next big tests for Argenx and its followers

Some believe that blocking FcRn has TNF-like potential, and J&J, Immunovant and UCB are all hot on Argenx’s heels.

Article image
Vantage logo
February 10, 2023

Jemperli moves towards neoadjuvant rectal cancer at last

Article image
Vantage logo
February 10, 2023

The world needs Garp, according to Abbvie

After years of slow progress, and with very little supporting clinical data, Abbvie pledges to push into a major Garp inhibition programme.

Article image
Vantage logo
January 31, 2023

Daiichi is so far the biggest Enhertu beneficiary

Article image
Vantage logo
January 25, 2023

Immuno-oncology goes subcutaneous

A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.

Article image
Vantage logo
January 25, 2023

Merck challenges Astra’s bile duct monopoly

Article image
Vantage logo
January 20, 2023

Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression

39% of the patients assessed carried this biomarker, the conference presentation reveals.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up